Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on the role of fedratinib in the treatment of myelofibrosis (MF), and further highlights the promising data that has emerged from recent clinical trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.